### Role of Old versus New P<sub>2</sub>Y12 Agents In ACS Patients: Focus on Ticagrelor



DR. VICTOR SEREBRUANY JOHNS HOPKINS UNIVERSITY HEARTDRUG RESEARCH LLC PUSAN, DECEMBER 2014

### Disclosures

- *Ownership:* Heart*Drug*<sup>TM</sup> Research, LLC
- *Grants:* Pfizer, Sanofi-BMS, Novartis, Lundbeck, Boehringer Ingelheim, Eli Lilly, AtheroGenics, Guilford, J&J, Bayer, Merck, Fibrex, Cardax, Eisai, Abbott, Pronova-GSK
- *Consulting:* Sanofi-BMS, McNeil, NPS Pharma, Bayer, Eisai, mutual funds, hedge funds
- Speaking: Sanofi-BMS, Boehringer Ingelheim
- *Legal:* Relator on behalf of US Government against AstraZeneca in sealed case BAH #12-1563 in Washington DC Federal Court
- *Patents:* Novartis (valsartan), Boehringer Ingelheim (Aggrenox), Eli Lilly (prasugrel), AtheroGenics (AGI-1067), Eisai (E-5555), Heart*Drug*<sup>™</sup> (ticagrelor, statins, PAR-1, sertraline, BleedScore)

# PLATO: Publishing the .... truth



## PLATO: Background

Variable	NEJM	FDA Reviews
Baseline Age (≥75 years)	15% for ticagrelor, 16% for clopidogrel	P=0.06
Past Medical History: Carotid Stenosis $(\geq 50\%)$	Not Reported	<ul><li>1.8% for ticagrelor,</li><li>2.3% for clopidogrel;</li><li>P=0.02</li></ul>

### PLATO: Outcomes

 Variable	NEJM	FDA Reviews
 Stroke	19 more for ticagrelor; P=0.22 for the difference	23 or 27 more for ticagrelor; P=0.09
Myocardial Infarction	89 more for clopidogrel	44 by sites, and 45 by ICAC extra adjudication exclusively to clopidogrel
Primary End Point	9.8% for ticagrelor, 11.7% for clopidogrel	At least 23 end point event for ticagrelor were inactivated, not adjudicated, soft-deleted or downgraded to "softer" endpoints.

O

0

-

## PLATO: Adverse Events

Event	NEJM	FDA-Reviews	
GI Ulcers/Perforations	Not reported	0.4% (n=38) for ticagrelor; 0.2% (n=18) for clopidogrel (P=0.009)	
Cerebrovascular accident	Not reported	0.7% (n=62) for ticagrelor; 0.5% (n=42) for clopidogrel (P=0.05)	
Other arterial thrombosis	19 patients (0.2%) after ticagrelor, and 31 patients (0.4%) after clopidogrel (p=0.09)	Peripheral ischemia with the relative risk (RR=1.3); claudication (RR=1.3); amputation (RR=1.4); pulmonary embolism (RR=1.5); and retinal ischemia (RR=1.3) were all more frequent for ticagrelor.	
Severe epistaxis	Not reported	0.4% (n=36) for ticagrelor; 0.1% (n=12) for clopidogrel (P=0.005)	

## PLATO: Conduct

Event	NEJM	FDA-Reviews
Blinding	Double-blind trial	At least 452 patients were unblinded prior to database lock
Premature withdrawal	Not reported	3.3% (n=307) for ticagrelor; 2.7% (n=255) for clopidogrel: (p=0.03)
Premature discontinuation	Slightly more common in the ticagrelor group than in the clopidogrel group (in 23.4% of patients vs. 21.5%); p-value not provided	23.7% (n=2186) for ticagrelor; 21.8% (n=1999) for clopidogrel (p=0.002 for the difference)
Withdrawn Informed Consent	Not reported	3.2% (n=296) for ticagrelor; 2.7% (n=249) for clopidogrel: (p=0.002 for the difference)

## PLATO: Conduct - II

Event	NEJM	FDA-Reviews
Lack of vital status	5 patients	At least 106 patients
Missing vital status follow up	Outpatient visits were scheduled at 1, 3, 6, 9, and 12 months	3.1% (n=289) for ticagrelor; 2.6% (n=242) for clopidogrel (p=0.04)
Alive at the end of study but no visit with vital signs on or after the earliest study completion date	Not reported	19.7% for ticagrelor; 18.1% for clopidogrel This difference (n=148) exceeds the difference in primary endpoint (n=147).

# PLATO: Integrity Challenge



Trust

### International Central Adjudication Committee in PLATO: No strangers, please

ICAC Role	DCRI	TIMI	UCRC	Sweden*	Others	
Co-Chairmen	1	-	1	-	-	
Coordinators	2	-	1	-	-	
Adjudicators	14	4	11	10	11**	
Study Sponsor	-	-	-	1	4***	

- DCRI Duke Clinical Research Institute, Durham, North Carolina, USA; TIMI – Thrombolysis in Myocardial Infarction, Boston, MA, USA; UCRC – Uppsala Clinical Research Center, Uppsala, Sweden
- = except UCRC, Uppsala, Sweden
  = including at least 5 former Duke cardiology fellows
- \*\*\* = from sponsor headquarters, Wilmington, Delaware, USA

## PLATO ICAC: At Your Service, Sire!

Who count Ticagrelor/Clopidogrel  $\Delta$  MI HR p-value

Sites	504/548	44	0.92	(0.095) NS
ICAC	504/ <b>593</b>	89	0.84	>0.001

Thromb Haemost, 2012

## PLATO: Efficacy Challenge



PLA	<b>Δ</b> Τ	$\cap$	Fff	ica	ACV	, "	M	aσ	ic"
• •				100	~ ~ y			<b>7</b> 0	


Variable	Sites	Adjudicated	FDA
Non-fatal MI's	-44	-89	-89
Non-fatal Strokes	+19	+19	+23/+27
Vascular Deaths	-89?	-89	-89
Baseline DM	25% e a	25% e a	25% e a
Baseline PAD	6.2% e a	6.2% e a	6.2 % e a
"-" Favors ticagrelor;	"+" favors clopidog	rel; "e a" – each arm	η

tritte put and put put the

### **Controversies in the clopidogrel PLATO arm**

Variable	C+A	Paradox
Vascular Death	5.1%	Extreme
All-cause mortality	5.9%	Unseen
MI/Death rate	6.9/5.1	74% - Absurd
Site Reported Events	0.095	Not significant


### US Outcomes in PLATO: Where are clopidogrel sudden deaths?



Source: R. Fiorentino, Clinical Reviewer

FDA Ticagrelor Review, 2010


# ATLANTIC: Under Scope



### Study population and design

- onset of ischaemic symptoms within 6 h
- Atlantic Population
   Planned for angioplasty (PCI)
   Planned for angioplasty (PCI)
   Planned for angioplasty (PCI)
   Planned for angioplasty (PCI)
   Pre-treated for STEMI in emergency rooms of non-PCI hospitals

#### **STE-ACS planned for PCI** (N = 1862)




### PLATO Angiographic Study Primary Endpoint: Post PCI TIMI Myocardial Perfusion Grade(TMPG)

	Overall	Ticagrelor	Clopidogrel	P value
	n (%)	n (%)	n (%)	
All Patients				
Normal (TMPG 3)	779/1657 (47.0)	396/841 (47.1)	383/816 ( <mark>46.9</mark> )	0.9608
STEMI				
Normal (TMPG 3)	412/989 (41.7)	213/502 (42.4)	199/487 (40.9)	0.6517
NSTE-ACS				
Normal (TMPG 3)	367/668 (54.9)	183/339 (54.0)	184/329 (55.9)	0.6411

### PLATO Angiographic Study: Post PCI TMPG by Aspirin Dose

	<b>a 1</b>				
	Overall	Ticagrelor	Clopidogrel	p-value	
	n (%)	n (%)	n (%)	Pvalue	
	N = 1657	N = 841	N = 816		
Aspirin Dose on Randomization Day					
Less than 100 mg					
Normal	168 (54.9)	82 (54.3)	86 (55.5)	0.0250	
Abnormal	138 (45.1)	69 (45.7)	69 (44.5)	0.8358	
100 – 299 mg					
Normal	180 (48.8)	93 (48.9)	87 (48.6)	0.0472	
Abnormal	189 (51.2)	97 (51.1)	92 (51.4)	0.9473	
300 mg or more					
Normal	431 (43.9)	221 ( <mark>44.2</mark> )	210 (43.6)	0.0420	
Abnormal	551 (56.1)	279 (55.8)	272 (56.4)	0.8420	
Aspirin Dose on Day 1 After	, <i>,</i> ,	· · ·	```'		
Randomization					
Less than 100 mg					
Normal	364 (46.8)	191 (47.4)	173 ( <mark>46.3</mark> )	0.7508	
Abnormal	413 (53.2)	212 (52.6)	201 (53.7)	0.7508	
100 – 299 mg					
Normal	345 (46.0)	171 (45.7)	174 (46.3)	0.9790	
Abnormal	405 (54.0)	203 (54.3)	202 (53.7)	0.8789	
300 mg or more					
Normal	69 (53.5)	33 (52.4)	36 (54.6)	0.8054	
Abnormal	60 (46.5)	30 (47.6)	30 (45.4)	0.8054	




### **Clinical endpoints at 30 days in ATLANTIC**

Values are %	Ticagrelor pre-hosp (n=906)	Ticagrelor in-hosp (n=952)	Odds ratio (95% CI)	p-value
Death (all-cause)	30 (3.3%)	19 (2.0%)	1.68 (0.94, 3.01)	0.08
Death (all-cause) 24 hours	12 (1.3%)	4 (0.4%)	3.18 (1.02-9.90)	0.043
мі	0.8	1.1	0.73 (0.28, 1.94)	0.53
Stroke	0.4	0.2	2.11 (0.39, 11.53)	0.39
ΤΙΑ	0	0.1		Not estimable
Urgent coronary revascularization	0.6	0.8	0.66 (0.21, 2.01)	0.46
Bail-out GP IIb/IIIa inhibitors	8.6	10.5	0.80 (0.59, 1.10)	0.17

e

### The Early PCI PLATO Death "Paradox"



The FDA Review of Complete Response; Thomas A. Marciniak, MD – Medical Team Leader, p.18

#### Impressions:

- Current data with ticagrelor are confusing, and ATLANTIC brings more uncertainty.
- The future of ticagrelor heavily depends on the confirmation of mortality benefit in PEGASIS (TIMI-54) trial
- Full disclosure and publication of the PHILO (NCT01294462) trial is needed to properly assess risks in Asians

